Results 31 to 40 of about 1,330 (154)

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center

Clinical and Applied Thrombosis/Hemostasis, 2019
Andexanet alfa is approved for the reversal of factor Xa inhibitors in patients with major bleeding events. We aimed to review the incidence of effective hemostasis with andexanet alfa in a real-world environment.
Victoria M. Stevens PharmD, Toby Trujillo PharmD, FCCP, FAHA, BCPS-AQ Cardiology, Scott W. Mueller PharmD, BCCCP, FCCM, Robert MacLaren PharmD, FCCM, FCCP, Paul M. Reynolds PharmD, BCCCP, Tyree H. Kiser PharmD, FCCM, FCCP, BCPS   +5 more
doaj   +1 more source

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists

Clinical and Applied Thrombosis/Hemostasis, 2022
Direct oral factor Xa inhibitors (DXIs) are approved for use in adult patients with non-valvular heart disease for stroke prevention, and the treatment/prevention of venous thromboembolism (VTE).
Vilmarie Rodriguez MD, MS, Joseph Stanek MS, Bryce A. Kerlin MD, Amy L. Dunn MD   +3 more
doaj   +1 more source

Abstract 1122‐000165: Endovascular Intervention for a Thrombotic Adverse Event During Andexanet Alfa Infusion

Stroke: Vascular and Interventional Neurology, 2021
Introduction: Andexanet alfa is the only specific reversal agent for factor Xa inhibitors and received FDA approval in 2018. Here we report an early infusion adverse event in a patient with acute intraventricular hemorrhage (IVH) that received Andexanet ...
Mohammad N Kayyali, Oana M Dumitrascu
doaj   +1 more source

A meta‐analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor–related major bleeding

Research and Practice in Thrombosis and Haemostasis, 2021
Background Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs).
Tessa Jaspers, Kimberly Shudofsky, Menno V. Huisman, Karina Meijer, Nakisa Khorsand   +4 more
doaj   +1 more source

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]

PLoS ONE, 2018
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu, Polly Pine, Janet M Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, John Malinowski, Stanley J Hollenbach, John T Curnutte, Pamela B Conley   +9 more
doaj   +1 more source

Case report: First treatment of acute ischaemic stroke in a patient on active rivaroxaban therapy using andexanet alfa and rtPA combined with early complete recovery

Frontiers in Neurology, 2023
Patients with non-large vessel occlusion acute ischemic stroke (NL-AIS) on oral anticoagulants (OAC) constitute the biggest portion among those who cannot receive any potential-reperfusion treatment even if they appear early in the hospital.
Bartosz Karaszewski, Bartosz Karaszewski, Sebastian Szczyrba, Sebastian Szczyrba, Bartosz Jabłoński, Bartosz Jabłoński, Dariusz Gąsecki, Dariusz Gąsecki, Piotr Kraszewski, Adam Wyszomirski, Robert Kowalski, Wioletta Kaliszan, Małgorzata Dąbrowska   +12 more
doaj   +1 more source

Andexanet alfa - what we know about this promising drug

Journal of Education, Health and Sport, 2023
Introduction and purpose. Andexanet alfa (AA) is a recombinant modified version of human activated factor X. It is used as an antidote for apixsaban and rivaroxaban when reversal of anticoagulation due to life-threatening or uncontrolled bleeding is ...
Natalia Ilnicka, Patrycja Zuziak, Maria Sadlik, Daria Matyja, Leila Abod   +4 more
doaj   +1 more source

Andexanet Alfa: First Global Approval [PDF]

Drugs, 2018
Intravenous andexanet alfa [coagulation factor Xa (recombinant), inactivated-zhzo; Andexxa®] is a first-in-class recombinant modified factor Xa protein that has been developed by Portola Pharmaceuticals as a universal antidote to reverse anticoagulant effects of direct or indirect factor Xa inhibitors.
openaire   +2 more sources

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, Volume 66, Issue 6, Page 1203-1209, June 2026.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source